How I treat NK/T-cell lymphomas

Tse, Eric; Kwong, Yok–Lam

doi:10.1182/blood-2013-01-453233

Cited by 270 publications

(302 citation statements)

References 75 publications

Supporting

Mentioning

286

Contrasting

Unclassified

Order By: Relevance

“…A recent report of 38 patients with widespread, relapsed, or refractory extranodal nasal NK/T-cell lymphoma utilizing the SMILE (dexamethasone, methotrexate, ifosfamide, L-asparaginase, and etoposide) regimen showed a 45% complete response rate and a 1-year survival of 55% [86]. At the present time, the SMILE regimen probably represents the best choice to reasonably fit patients with wide-spread disease and could be considered as adjuvant therapy in patients with local regional disease [89].…”

Section: Nk/t-cell Lymphomamentioning

confidence: 93%

The aggressive peripheral T‐cell lymphomas: 2015

Armitage

2015

American J Hematol

View full text Add to dashboard Cite

Background: T‐cell lymphomas make up approximately 10%–15% of lymphoid malignancies. The frequency of these lymphomas varies geographically, with the highest incidence in parts of Asia.Diagnosis: The diagnosis of aggressive peripheral T‐cell lymphoma (PTCL) is usually made using the World Health Organization classification. The ability of hematopathologists to reproducibly diagnosis aggressive PTCL is lower than that for aggressive B‐cell lymphomas, with a range of 72%–97% for the aggressive PTCLs.Risk Stratification: Patients with aggressive PTCL are staged using the Ann Arbor Classification. Although somewhat controversial, positron emission tomography scans seem to be useful as they are in aggressive B‐cell lymphomas. The most commonly used prognostic index is the International Prognostic Index. The specific subtype of aggressive PTCL is an important risk factor, with the best survival seen in anaplastic large‐cell lymphoma—particularly young patients with the anaplastic lymphoma kinase positive subtype.Risk‐Adapted Therapy: Anaplastic large‐cell lymphoma is the only subgroup to have a good response to a CHOP‐like regimen. Angioimmunoblastic T‐cell lymphoma has a prolonged disease‐free survival in only ∼20% of patients, but younger patients who have an autotransplant in remission seem to do better. PTCL‐not otherwise specified is not one disease. Anthracycline‐containing regimens have disappointing results, and a new approach is needed. Natural killer/T‐cell lymphoma localized to the nose and nasal sinuses seems to be best treated with radiotherapy‐containing regimens. Enteropathy‐associated PTCL and hepatosplenic PTCL are rare disorders with a generally poor response to therapy, although selected patients with enteropathy‐associated PTCL seem to benefit from intensive therapy. Am. J. Hematol. 90:666–673, 2015. © 2015 Wiley Periodicals, Inc.

show abstract

Section: Nk/t-cell Lymphomamentioning

confidence: 93%

The aggressive peripheral T‐cell lymphomas: 2015

Armitage

2015

American J Hematol

View full text Add to dashboard Cite

show abstract

“…For recurrent and extensive disease, various chemotherapy regime as SMILE, VIPD, GELOX, GOLD have been devised but there use as a guideline is yet not validated. [4] For patients with NK/T-cell leukemia and advanced stage lymphoma, autolog ous hematopoietic stem cell transplantation is recommended.…”

Section: Discussionmentioning

confidence: 99%

“…[3] Optimal treatment therapy is yet not validated. [4] We hereby report a rare case of extranodal NHL of nasal type with predominant T-cell markers, who was refractory to CHOP regime and responding to treatment with SMILE regime. [5] …”

Section: Introductionmentioning

confidence: 99%

Extranodal NK/T-cell lymphoma of the nasal type with predominant T-cell markers: A rare subtype of rare disease entity

Varshney¹,

Patidar²,

Malhotra³

et al. 2015

Int J Med Public Health

View full text Add to dashboard Cite

“…Stage, surrogately detected by circulating EBV DNA plasma levels is of prognostic significance, [117][118][119] with chemoradiation regimens achieving 70-80% 5-year survival rates. 118,120 The outcome for plasmacytoma is better than multiple myeloma, with patients managed by localized radiation. 108,121 …”

Section: Nut Carcinoma (Squamous Cell Carcinoma)mentioning

confidence: 99%

Small round blue cell tumors of the sinonasal tract: a differential diagnosis approach

Thompson

2017

Modern Pathology

View full text Add to dashboard Cite

One of the most challenging diagnostic categories within tumors of the sinonasal tract is the small round blue cell tumors. Biopsies are usually small and limited, resulting in considerable diagnostic difficulty for practicing surgical pathologists. These tumors share several overlapping histologic and immunophenotypic findings while also showing considerable variation within and between cases. Specific tumor site of origin, imaging findings, and clinical findings must be combined with the histology and pertinent ancillary studies if the correct diagnosis is to be reached. Discrimination between neoplasms is critical as there are significant differences in therapy and overall outcome. It is important to have a well developed differential diagnosis for this category of tumors, where each of the diagnoses is considered, evaluated, and either confirmed or excluded from further consideration. In an undifferentiated tumor, showing a small round blue cell morphology, using the mnemonic 'MR SLEEP' helps to highlight tumors to consider: melanoma, mesenchymal chondrosarcoma, rhabdomyosarcoma, sinonasal undifferentiated carcinoma, squamous cell carcinoma (including NUT carcinoma), small cell osteosarcoma, lymphoma, esthesioneuroblastoma (olfactory neuroblastoma), Ewing sarcoma/primitive neuroectodermal tumor, pituitary adenoma, and plasmacytoma. A panel of pertinent immunohistochemistry studies, histochemistries and/or molecular tests should aid in reaching a diagnosis, especially when taking the pattern and intensity of reactions into consideration.

show abstract

How I treat NK/T-cell lymphomas

Cited by 270 publications

References 75 publications

The aggressive peripheral T‐cell lymphomas: 2015

The aggressive peripheral T‐cell lymphomas: 2015

Extranodal NK/T-cell lymphoma of the nasal type with predominant T-cell markers: A rare subtype of rare disease entity

Small round blue cell tumors of the sinonasal tract: a differential diagnosis approach

Contact Info

Product

Resources

About